Pfizer Inc's chief executive said on Tuesday that almost 250,000 courses of the drugmaker's oral antiviral COVID-19 treatment Paxlovid were being administered per week as cases surged in the United States.

About 250,000 courses of COVID pill Paxlovid being administered per week - Pfizer CEO

Researchers discovered molnupiravir-associated mutational signatures in SARS-CoV-2 genomes.

Medication and mutations: molnupiravir's impact on SARS-CoV-2 genomes

Covid-19 viruses with distinctive patterns of mutation are appearing in countries that use a drug called molnupiravir, however, none of these is a variant of concern.

Covid-19 drug may be creating new variants with distinctive mutations

Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient.

Covid antiviral drug linked to ‘transmissible’ mutations, research finds

First antiviral drug for Covid may have created mutations, scientists find.

First antiviral drug for Covid may have created mutations, scientists find

A real-world study found that Pfizer's COVID-19 antiviral Paxlovid is now less effective at preventing hospitalization or death in high-risk patients as compared with earlier studies.

Paxlovid Weaker Against Current COVID-19 Variants

Westvac Biopharma Co. Ltd. has described keto amide derivatives acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).